These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 24550332)

  • 41. Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment.
    Kurata A; Yoshida T; Inoue M; Ishizuka T; Nakatsu T; Shimizu T; Kato M; Nishikawa Y; Ishizuka H
    Adv Ther; 2020 Jan; 37(1):253-264. PubMed ID: 31705436
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics, safety and tolerability of a single oral dose of maraviroc in HIV-negative subjects with mild and moderate hepatic impairment.
    Abel S; Davis JD; Ridgway CE; Hamlin JC; Vourvahis M
    Antivir Ther; 2009; 14(6):831-7. PubMed ID: 19812445
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients.
    White KL; Kulkarni R; McColl DJ; Rhee MS; Szwarcberg J; Cheng AK; Miller MD
    Antivir Ther; 2015; 20(3):317-27. PubMed ID: 25321623
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The pharmacokinetics, pharmacodynamics and clinical efficacy of elvitegravir + cobicistat + emtricitabine + tenofovir combination therapy for the treatment of HIV.
    Raffe S; Fisher M
    Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):427-35. PubMed ID: 25553805
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetic and Tissue Distribution Profile of Long Acting Tenofovir Alafenamide and Elvitegravir Loaded Nanoparticles in Humanized Mice Model.
    Prathipati PK; Mandal S; Pon G; Vivekanandan R; Destache CJ
    Pharm Res; 2017 Dec; 34(12):2749-2755. PubMed ID: 28905173
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An open-label, single-dose, parallel-group study of the effects of chronic hepatic impairment on the safety and pharmacokinetics of desvenlafaxine.
    Baird-Bellaire S; Behrle JA; Parker VD; Patat A; Paul J; Nichols AI
    Clin Ther; 2013 Jun; 35(6):782-94. PubMed ID: 23623756
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Population Pharmacokinetics Study of Nemonoxacin Among Chinese Patients With Moderate Hepatic Impairment.
    Kang Y; Li Y; Xu F; Zhang J; Wang K; Chen Y; Wu J; Guo B; Yu J; Zhang Y
    Clin Ther; 2019 Mar; 41(3):505-517.e0. PubMed ID: 30819510
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study.
    Harris M; Ganase B; Watson B; Harrigan PR; Montaner JSG; Hull MW
    AIDS Res Ther; 2017 Nov; 14(1):59. PubMed ID: 29096670
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir.
    Ramanathan S; Mathias AA; German P; Kearney BP
    Clin Pharmacokinet; 2011 Apr; 50(4):229-44. PubMed ID: 21348537
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project.
    Squillace N; Ricci E; Quirino T; Gori A; Bandera A; Carenzi L; De Socio GV; Orofino G; Martinelli C; Madeddu G; Rusconi S; Maggi P; Celesia BM; Cordier L; Vichi F; Calza L; Falasca K; Di Biagio A; Pellicanò GF; Bonfanti P;
    PLoS One; 2017; 12(6):e0179254. PubMed ID: 28632758
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function.
    Treitel M; Marbury T; Preston RA; Triantafyllou I; Feely W; O'Mara E; Kasserra C; Gupta S; Hughes EA
    Clin Pharmacokinet; 2012 Sep; 51(9):619-28. PubMed ID: 22799589
    [TBL] [Abstract][Full Text] [Related]  

  • 52. HIV-2 antiviral potency and selection of drug resistance mutations by the integrase strand transfer inhibitor elvitegravir and NRTIs emtricitabine and tenofovir in vitro.
    Andreatta K; Miller MD; White KL
    J Acquir Immune Defic Syndr; 2013 Apr; 62(4):367-74. PubMed ID: 23187937
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An effect of moderate hepatic impairment on the pharmacokinetics and safety of darapladib.
    Magee MH; Shearn S; Shaddinger B; Fang Z; Glaser R
    Br J Clin Pharmacol; 2014 Nov; 78(5):1014-21. PubMed ID: 24938621
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment.
    Jin F; Robeson M; Zhou H; Hisoire G; Ramanathan S
    J Clin Pharmacol; 2015 Aug; 55(8):944-52. PubMed ID: 25821156
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A randomized trial in healthy subjects to assess the bioequivalence of an atazanavir/cobicistat fixed-dose combination tablet versus administration as separate agents.
    Sevinsky H; Tao X; Wang R; Ravindran P; Sims K; Xu X; Jariwala N; Bertz R
    Antivir Ther; 2015; 20(5):493-500. PubMed ID: 25361436
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Renal insufficiency has no effect on the pharmacokinetics of vicriviroc in a ritonavir-containing regimen.
    Kasserra C; Sansone-Parsons A; Keung A; Tetteh E; Assaf M; O'Mara E; Marbury T
    Clin Pharmacokinet; 2010 Jun; 49(6):397-406. PubMed ID: 20481650
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Asenapine pharmacokinetics in hepatic and renal impairment.
    Peeters P; Bockbrader H; Spaans E; Dogterom P; Lasseter K; Marbury T; Gibson GL; de Greef R
    Clin Pharmacokinet; 2011 Jul; 50(7):471-81. PubMed ID: 21651314
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics, safety, and tolerability of maraviroc in HIV-negative subjects with impaired renal function.
    Vourvahis M; Fang J; Checchio T; Milton A; Weatherley B; McFadyen L; Heera J
    HIV Clin Trials; 2013; 14(3):99-109. PubMed ID: 23835512
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of rifabutin on the pharmacokinetics of oral cabotegravir in healthy subjects.
    Ford SL; Lou Y; Lewis N; Kostapanos M; D'Amico R; Spreen W; Patel P
    Antivir Ther; 2019; 24(4):301-308. PubMed ID: 30896438
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers.
    Zhao Q; Iyer GR; Verhaeghe T; Truyen L
    J Clin Pharmacol; 2002 Apr; 42(4):428-36. PubMed ID: 11936568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.